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Abstract
Title: Examining the Impact of Illicit Drug Use on Prescribed Psychotropic
Medication Adherence
Author: Lauren Natalie Stroker, M.S., BCBA
Committee Chair: Patrick J. Aragon, Psy.D.
The ever-increasing rates of prescription drug utilization in the United States,
coupled with the high rates of non-adherence to psychotropic medications by
patients, makes this area of research an increasingly important field of study.
Previous studies have elucidated the critical factor medication adherence plays in
the effectiveness of treatment and overall clinical outcomes for patients and the
deleterious effect of non-adherence; one of them being substance (ab)use. The
present study was conducted in an effort to add to the existing literature examining
medication nonadherence and substance use. The current study looked to expand
the research examining the relationship between substance use and non-compliant
medication behavior, as well as evaluate the effect of intensity of substance use on
non-adherence among a community mental health setting. Results of our study
found 73 percent of participants engaged in illicit drug and alcohol use, and 50.3
percent of participants reported being non-adherent to medications. Contrary to the
previous research, the current study found substance use had no significant effect
on medication non-adherence, t(195) = -.64, p = .57. Additionally, intensity
(frequency) of substances used had no significant effect on non-adherence to
psychotropic medication, t(163) = 1.18, p = .24. Lastly, no relationship was found
iii

between the intensity (frequency) of substances used and non-adherence to
psychotropic medication, r(163) = - .11, p > .05. Results obtained in this study
continue to highlight the high frequency of patients utilizing substances
concurrently with prescribed medications. Although the current study did not find
substance use and intensity of use to have a statistically significant effect on
medication non-adherence, the information gathered throughout this study remains
important not only for medical professionals but also clinicians. Gaining a greater
understanding of the factors influencing non-adherence is advantageous in the
development of strategies to increase adherence in patients and improve overall
patient outcomes.
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Examining the Impact of Illicit Drug Use on Prescribed Psychotropic
Medication Adherence
Prevalence
Recent research has noted a significant growth in prescription drug use
amongst adults in the United States (Kantor et al., 2015). An evaluation of
prescription drug use in the United States, conducted by Kantor and colleagues
(2015), showed a 9% increase in the use of prescription drugs from 1999-2012.
Specifically, they indicated that in 1999-2000, 51% of US adults reported using a
prescription drug, which increased to approximately 59% in 2011–2012. According
to research conducted within the Mayo Clinic (2013), 7 in 10 Americans were
found to use prescription drugs. Their research indicated that approximately 70
percent of individuals in the United States were taking at least one prescribed
medication (Mayo Clinic, 2013). The Center for Disease Control and Prevention
reported that in 2015, approximately 3.7 billion prescriptions were ordered by
physicians. These billions of prescriptions highlight the “epidemic” levels of
prescription drug use noted by McHugh and colleagues (2014).
The previous findings denoted not only a statistically significant increasing
trend in prescription drug use within the United States, but also pinpointed an
important area for further research. With the high and ever-increasing rates of
prescription drug utilization within the United States, research has been conducted
to examine specifically, the type of drugs most utilized. Research within the Mayo
1

Clinic has also elucidated the most prevalently prescribed medications within the
US. Through their research, they discovered the most frequently prescribed
medication to be antibiotics and medications related to heart disease and diabetes.
Notably, is the report that the second and third most popularly prescribed
medication was found to be antidepressants and opioids, respectively (Mayo Clinic,
2013). Similarly, the Substance Abuse and Mental Health Services Administration,
using the Survey on Drug Use and Health in 2016, found approximately 37.1% of
US adults with a mental illness reported taking prescribed medications (Substance
Abuse and Mental Health Services, 2012).
Prescription Drug Use
Moore and Mattison (2017) utilized data from the 2013 Medical
Expenditure Panel Survey to examine more thoroughly the percentage of adults
who used antidepressant, anxiolytics, sedatives, hypnotics and antipsychotics
within the United States. The results of their study showed 16.7% of individuals
who were surveyed, had indicated filling one or more prescriptions for one of the
aforementioned drugs in 2013. That is, of the 242 million people participating
within the Medical Expenditure Survey, 1/6 had utilized a psychiatric drug
obtained through prescription. More specifically, 12% of individuals reported the
antidepressant use and 8.3% indicated the use of either an anxiolytic, sedative or
hypnotic (Moore & Mattison, 2017). And finally, results of the study indicated that
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an estimated 1.6% of individuals surveyed reported the use of antipsychotic
medications (Moore & Mattison, 2017).
Whereas one might assume an increase in psychotropic medication use is
suggestive on an increase in mental health diagnoses across the country, this may
not be the case. In fact, research conducted by Olfson and Marcus (2009) indicated
the opposite to be true.
Olfson and Marcus (2009) examined the national trends surrounding
antidepressants prescription use. Utilizing data obtained from the household
component of the 1996 and 2005 Medical Expenditure Panel Surveys (MEPSs), the
authors looked to examine the overall rate of antidepressant use along with sociodemographic and clinical features such as age, sex, race, and self-perceived mental
health. Their study demonstrated that overall, there was a 4.28% increase in the
prescription of antidepressant medications, from 1996-2005 (Olfson & Marcus,
2009). This 4.28% is representative of an increase from 13.3 million to 27 million
people utilizing antidepressants (Olfson & Marcus, 2009).
The study also revealed an important piece of information regarding the rate
of mental health diagnoses. The authors reported that although the rate of
antidepressant medication prescription has increased, the number of individuals
receiving a depression diagnosis did not show a significant increase overall.
Specifically, the study reported 26.25% of patients in 1996 were being treated for
depression, which was found to be comparable to 26.85% in 2005 (Olfson &
3

Marcus, 2009).
As such, the study highlights the fact that psychotropic medication use is
increasing, irrespective of an increase in psychiatric diagnoses. It notes an increase
of 13.7 million individuals utilizing antidepressant medication from 1996-2005
with a negligible change in diagnostic rates during that time. Therefore, it can be
suggested that prescription drugs are now being prescribed more frequently as a
treatment method for previously diagnosed mental health patients. As this method
of treatment gains popularity, so too does the study of these medications and the
effects of their proper and improper use.
Medication Adherence and Non-Adherence
Cramer et al., (2008) defined medication adherence as, “the act of
conforming to the recommendations made by the provider, with respect to timing,
dosage and frequency of medication taking.” The World Health Organization
defines medication adherence as “the degree to which a person’s behavior
corresponds with the agreed recommendations from a health care provider.”
Conversely, additional studies identify non-adherence simply as a failure to take
medication as prescribed (Jimmy & Jose, 2011). Another factor of non-adherence,
elucidated by the literature, is the behaviors ability to be differentiated into covert
or undisclosed or overt non-adherence.
Mitchell and Selmes (2007), in their review of previous literature on nonadherence, define covert and overt non-adherence Covert non-adherence is defined
4

as undisclosed discontinuation of medication. In other words, this form of nonadherence is out of the awareness of the clinician or provider. Overt non-adherence
alternatively occurs at the onset of treatment and can be better defined as a patient’s
refusal to engage in treatment prescribed by the medical provider. Haddad, Brain,
and Scott (2014) note that covert non-adherence can lead clinicians to a false
conclusion that the medications are simply not effective for the individual, which in
fact, may not be the case (Haddad et al., 2014). It is also noted that covert nonadherence is usually the result of a clinician not making sufficient effort or taking
an adequate amount of time to assess, in a non-judgmental way, the patients past
and current medication adherence (Haddad et al., 2014).
Jawad, Watson, Haddad, Talbot and McAllister-Williams (2018) reported
that the category of non-adherence can be divided further into non-adherence,
which is deliberate, and non-intentional non-adherence. Research conducted by the
World Health Organization regarding medication non-adherence also makes this
distinction.
Jawad and collogues (2018) indicated that non-intentional non-adherence
can be the result of forgetfulness, difficulty seeing the prescription, difficulty with
obtaining the medication due to financial means, and poor description of the
instructions from the prescriber. Non-adherence, which is deliberate, is a result of
the patient making “a conscious decision to utilize less than the prescribed amount
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of a medication,” or otherwise decided change or avoidance to the prescription plan
(Jawad et al., 2018).
Medication adherence can be further broken down into degrees of nonadherence. Jawad and colleagues (2018) stated that patient adherence with
medication lies on a spectrum, ranging from total adherence to zero adherence with
varying degrees of partial adherence lying between. Notably they also indicated
that adherence should be viewed as more of a dynamic factor, which has the
likelihood to change across time. The authors noted that patient’s behavior may
change and that those who “adhere well at one time may adhere poorly at another
time.”
Across studies of medication adherence, there has been significant
variability in the definition used to evaluate non-adherence (Jawad et al., 2018).
This variability has been identified as a significant limitation within the research
(Brown & Bussell, 2011). Non-adherence to medication, however, regardless of the
distinction of deliberate or unintentional, and the definition used to evaluate the
behavior, has been shown to affect not only the patient’s overall well-being, but
also his/her treatment outcome and associated medical costs.
Effect of Non-Adherence
With the increase in prescription drug use by patients, comes the need for
further research on medication-related behaviors; specifically, adherence to these
prescribed medications. The importance of medication adherence cannot be
6

understated, as research indicates non-adherence to medication, especially
psychiatric medications, results in several negative outcomes for both the patient as
well as the overall health care system.
Non-adherence with medication has been shown to be associated with
higher rates of mortality and suicide (Chapman & Horne, 2013; De Las Cuevas et
al., 2017; Magura et al., 2014). Additionally, non-adherence with treatment has
been shown to result in higher rates of relapse, suicidality and hospitalization
(Jaward et al., 2018; Zivin et al., 2009). In addition to the negative effect that nonadherence has been shown to have on patient outcome, non-adherence with
medication has also be shown to be associated with higher medical costs as well.
Joe and Lee (2016) examined the effect of medication non-adherence in
individuals with schizophrenia; on both psychiatric and non-psychiatric medical
care costs. Data was gathered through the Health Insurance Review and
Assessment Service-National Patients Sample, a Korean insurance database. The
authors placed selected individuals into two groups: the first an adherent versus
non-adherent group and the second a persistent versus non-persistent group, with
participants being 5,548 individuals and 3,912, respectively (Joe & Lee, 2016). The
authors also noted that they used a matching method to address any possible effects
of insurance plan or time of follow up on service utilization costs. The differences
of service utilization costs between groups were then compared. The authors found
higher non-psychiatric service utilization in patients who were non-compliant with
7

their psychotropic medications. The authors cited a tendency toward poor self-care
and unhealthy lifestyle choices common in individuals with severe mental illness
(Joe & Lee, 2016). Additionally, the results indicated higher health care costs for
non-compliant individuals with schizophrenia and suggested this may be due to the
high rate of medical comorbidities associated with this. Furthermore, the authors
noted that compliant individuals used psychiatric services significantly more than
non-compliant patients. The authors hypothesized that this difference may be due
to the fact that individuals who have a tendency toward non-adherence with
medication, also are more likely to avoid utilization of these services (Joe & Lee,
2016).
Similar data was gathered for individuals with Bipolar Disorders as well. A
study conducted by Gianfrancessco, Sajativic, Rajagopalan and Wang (2008) found
a relationship between non-adherence to medication and health care expenditure.
They reported improved adherence to medication resulted in lower overall
outpatient mental healthcare cost. Specifically, they examined medical expenditure
in two groups of individuals; those diagnosed with bipolar disorder for whom had
either predominantly manic symptoms or those diagnosed with bipolar disorder for
whom were diagnosed with predominantly depressive symptoms. During the study
medication adherence was evaluated using a medication possession ratio (MPR).
The ratio is obtained by dividing the number of pills indicated on the prescription
by the number of days before the prescription was refilled (Gianfrancessco et al.,
8

2008). This gives the experimenters an idea of how compliant patients are with
taking their prescribed medication. A larger MPR is reflective of greater adherence.
These measurements were conducted in 4-month treatment segments across 15
months to examine an additional variable of consistency with treatment
(Gianfrancessco et al., 2008).
Results of this study indicated that within the manic group, higher MPR
across these segments resulted in a total health care expenditure reduction of
between $123 and $439. Individuals with predominantly depressive symptoms
showed a statistically significant reduction of total expenditure of $714 at 10-12
months. Data indicated increased medication adherence in both groups resulted in a
statistically significant decreased in their medical expenditure across 15 months
(Gianfrancessco et al., 2008). Additionally, the authors noted a $468 decrease in
expenditure in the area of outpatient mental health, specifically. Outpatient mental
health was reported to be a measure of mental health care costs for individuals
outside of prescribed antipsychotics. Results indicated that at baseline, the medical
expenditure for the manic group in this area was $2,757 and the depressive group
was $2,687 (Gianfrancessco et al., 2008). The authors noted that individuals who
showed higher MPR scores (higher adherence with medication) were more
stabilized and therefore, required fewer health care resources.

9

Rates of Non-Adherence
Much of the previous research has focused on examining rates of
medication adherence among specific populations. Jimmy and Jose (2011)
indicated that across several studies, which were found to have examined adherence
behavior, the percentage or rate of medication adherence varied drastically from a
very low 10% to up to 92 % (Jimmy & Jose, 2011). The authors noted that
medication adherence for individuals, with more chronic illnesses, were especially
low. The authors stated that these individuals had a tendency to take their
prescribed medication only 50% of the time.
Patients with psychiatric disorders have been shown to be least likely to
comply with medication: including frequency, duration, and initial acceptance of
the medication. Research on adherence, across psychiatric disorders, has found
variable rates of non-adherence. Although variable, these rates of non-adherence
have been shown to be significant and illuminate the treatment challenges faced by
both clinicians and providers.
Sansone and Sansone (2012) conducted a literature review to examine
documented rates of no adherence in psychiatric populations; specifically,
individuals who were prescribed antidepressant medication. The literature review
identified five studies, which were conducted in the United States and Asia. After
examining the previous literature, authors discovered non-adherence rates ranging
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from 13 to 55.7 percent. Additionally, they found the average non-adherence rate,
across the studies, to be 52 percent overall (Sansone &Sansone, 2012).
Eticha, Teklu, Ali, Solomon and Alemayehu (2015) investigated adherence
with medication in individuals with schizophrenia. The cross-sectional study was
conducting using patients with a diagnosis of schizophrenia receiving services
across two hospitals in Ethiopia. Three hundred and ninety-three patients met
inclusion criteria and were interviewed using a questionnaire eliciting information
regarding sociodemographic variables, insight, and beliefs about treatment,
medication adherence, side effects and medication satisfaction. In regard to
medication adherence, the study found 26.5% of participants were non-adherent
with prescribed antipsychotic medication (Eticha et al., 2015).
A study conducted by Kamali et al., (2006) also noted a high rate of nonadherence to medication among participants diagnosed with schizophrenia. The
study indicated of the 100 patients included within their study, one third were
found to be non-compliant with antipsychotic medications.
Chakrabarti (2017) conducted a met analysis of 132 articles examining
medication non-adherence in individuals with Bipolar disorder. This examination
found mean rates of non-adherence across all studies to be 41.5-43 percent. The
authors noted that medication non-adherence was found in approximately one third
of patient’s diagnosed with Bipolar disorder (Chakrabarti, 2017).
Stein, Cantrell, Sokol, Eaddy and Sah (2006) utilized a manage care database
11

to examined rates of adherence by patients prescribed with a selective serotonin
reuptake inhibitors (SSRIs) for management of an Anxiety Disorder. The authors
indicated that of the 13,085 patients included in the study, 57 percent of these
individuals were non-adherent to their prescribed medication. These high
percentages of non-adherence to medication reflect a significant area in need of
improvement and therefore, important areas for further research.
Factors Associated with Non-Adherence
Julius, Novitsky and Dubin (2009) conducted a literature review to elucidate
factors consistently identified within the previous research to be risk factors for
medication non-adherence. The authors then categorized these factors into 4 main
areas; patient-related, psychological, medication-related and social/environmental.
They noted patient-related factors, such as the individual being: young for his/her
age, unmarried, and with a lower education level; all served as barriers to
psychiatric medication non-adherence. Having little insight, experiencing denial,
and negative attitudes toward medication; was identified as psychological barriers
(Julius et al., 2009). Additionally, medication related barriers included factors such
as possible negative side effects, frequency of dosage, and perceived efficacy of the
medication by the patient. It was also noted that factors such as the quality of the
therapeutic alliance, support from family members and supervision of the
medication’s administration, could also function as possible barriers to medication
adherence (Julius et al., 2009). In addition, Gellad, Grenard, and Marcum (2011)
12

found patient's limited overall knowledge of their disease and basic health
information also functioned as a barrier to medication adherence.
Chandra, Kumar, and Reddy (2014) studied patients diagnosed with
schizophrenia and factors contributing to medication non-adherence. They found,
like the previous authors, that younger age and poor insight into their illness were
factors associated with non-adherence in patients (Chandra et al., 2014, Eticha et
al., 2015). Additionally, their study indicated unemployment and negative attitudes
toward medication were also significant predictors for non-adherence. Similarly,
Chapman and Horne (2013) identified practical reasons such as resources and
affordability to be additional factors influencing an individual’s adherence ability.
Another crucial barrier indicated by previous research, and the one that will be
focused on within the current research is polypharmacy (Gellad et al., 2012).
Polypharmacy
Polypharmacy or polysubstance use refers to the use of “multiple substances
within a specific period of time” (Conway et al., 2013). Polypharmacy can be a
result of multiple drugs prescribed by a physician, or multiple physicians, but can
also be the result of drug misuse and abuse (Omenka & Green, 2017). Additionally,
polypharmacy can include the use of combination of medications used concurrently
with illicit substances (Masnoon et al., 2017; Omenka & Green, 2017).
For the mental health population, the study of polypharmacy is especially
important, as medication is a common treatment modality for many mental
13

illnesses and rates of psychotropic mediation prescription are only increasing. The
high rate of psychotropic medication use, coupled with the high rate of comorbidity
with substance use disorder, lays the groundwork for polypharmacy within this
population.
Statistics obtained from a survey conducted by the Substance Abuse and
Mental Health Services Administration (SAMHSA) in 2016, indicated
approximately 8.2 million adults within the United States have co-occurring mental
and substance use disorders. It was noted as well that of the population identified
by SAMHSA, individuals with comorbid substance use disorders make up 18.5
percent of mental health illnesses (Substance Abuse and Mental Health Services
Administration, 2017). Of the population of 2.4 million that SAMHSA identified to
have a serious mental illness, 2.4% of those individuals were identified to also meet
criteria for a substance use disorder (SAMHSA, 2017). The high comorbidity of
mental illness and substance use places this population at a particularly high risk
for polypharmacy and in turn for difficulties with medication adherence.
Additionally, the study of polypharmacy is important, as drug-drug interactions that
result from this behavior can have drastic effects on the individual.
Drug-drug Interactions
Drug-drug interactions can result in two different effects within the body:
pharmacodynamics or pharmacokinetics (Cascorbi, 2012; Lindsey et al., 2012).
Pharmacodynamics refers to an interaction, which modifies, enhances, or weakens
14

the effect of a drug. While pharmacokinetic effects modify the, “absorption,
distribution, metabolism or excretion of the drug” (Lindsey et al., 2012).
Research has indicated significant interactions between psychotropic and
illicit drugs (Lindsey et al., 2012). Individuals who utilized both drugs
concurrently can experience numerous adverse side effects such as mental status
changes and sleep difficulty (Malik and Kumar, 2012, Morton, 1999). Furthermore,
changes in blood pressure and heart rate (Barr et al., 2006), inhibited respiratory
function and induce sedation (Pathan & Williams, 2012), heightened effect of a
drug (Cheng et al., 2018), CNS depression and coma (Lindsey et al., 2012) and
death are all examples of documented medication-related side effects (Jones and
McAnich, 2015). In addition to these side effects, the use of concurrent
psychotropic medication and illicit drugs also can result in poorer health outcomes
and a potential exacerbation of symptoms (Cascorbi, 2012; Lindsey et al., 2012).
Alcohol. Psychotropic medications when used with alcohol can result in
several adverse side effects. Alcohol has been shown to affect the enzymes required
for prescription drug metabolism (Cheng et al., 2018). As such, acute use of alcohol
may result in the drug not being metabolized properly. The medication may then
remain in the individual’s system for longer, continuing to influence the individual
for a prolonged period of time. Cheng and colleagues (2018) indicated that more
chronic use of alcohol also effects metabolism of medication, but in an opposing
manner. They noted that when alcohol is used in a more chronic fashion, increased
15

enzymes may be produced which results in the expedited metabolism of
medications. As such, the chronic use of alcohol can result in a lessening of the
effect of the medication all-together (Cheng et al., 2018).
The authors noted that medications also have the ability to influence the
effect of the alcohol as well. Medications may decrease an individual’s alcohol
threshold resulting in the individual needing to consume less alcohol to reach the
point of intoxication; increasing the potential for adverse effects (Cheng et al.,
2018). As psychotropic medications often work through an inhibitory effect on the
central nervous system, as was previously stated, alcohol can enhance these
inhibitory effects, diminishing the individual’s ability to function as well
(Weathermon & Crabb, 1999). With the numerous negative side effects that come
as a result of the concurrent use of alcohol and psychotropic prescription
medication, the question of the client’s knowledge of these significant
consequences is raised.
The study conducted by Cheng, Mithoowani, Ungar and Lee (2018)
examined patients with mental health disorders perceptions and knowledge of
alcohol drug interactions. When asked whether the participants had received
information about the negative side effects of the use of alcohol with medication,
75 percent of patients indicated they had received this information and indicated
that it was satisfactory (Cheng et al, 2018). In addition, participants were asked if
they follow the prescribed recommendations. The results indicated that only 65%
16

do in fact avoid the use of alcohol with their medication (Cheng et al., 2018).
Cocaine. Cocaine is a substance, which affects several neurotransmitters in
the brain including dopamine, norepinephrine and serotonin. It’s ability to bind
with neurotransmitter transporters in the synapse inhibits the removal of the
neurotransmitters and allows them to remain in the synapse and bring about the
common positive symptoms associated with the drug: pleasure, sense of well-being
and alertness, etc. (Morton, 1999). Cocaine also has the potential to bring about
negative effects such as symptoms of psychosis, paranoia, suspiciousness, as well
as difficulties with sleep (Morton, 1999).
The mechanism, by which cocaine brings about these effects within the body,
reinforces the potential for adverse interactions when mixed with psychotropic
medication. As psychotropic medications also influence the production,
maintenance and removal of these neurotransmitters within the brain, the added
effects of the cocaine can be detrimental to the effectiveness of the medication, as
well as the overall health of the individual.
Antidepressant medications work by increasing the amount of serotonin that
is available within the brain. When used concurrently with cocaine, increased
serotonin levels can lead to serotonin syndrome. Malik and Kumar (2012) describe
this syndrome as a potentially life-threatening condition, which is a result of excess
serotonin in the nervous system. This excess can lead to changes in one’s mental
status, autonomic dysfunction and neuromuscular hyperactivity (Malik and Kumar,
17

2012).
Opioids. Opioids’ sedative and analgesic effects come about through their
agonist effect on three opioid receptor subtypes (Pathan & Williams, 2012).
Binding of an opioid to these receptor types results in an analgesic effect. Along
with its analgesic effect, opioids, when binding to receptors, also have the potential
to inhibit respiratory function and induce sedation (Pathan & Williams, 2012).
Opioids, when used with benzodiazepines and Monoamine oxidaseinhibitor’s (MAOI) have the potential to result in central nervous system depression
and sedation (Lindsey et al., 2012, Saber-Tehrani et al., 2011,). Jones, Mogali and
Comer (2012) investigated the combined use of opioids and benzodiazepines and
examined their pharmacological interactions. It was noted that as these drugs have
similar effects on the body, and as such, their concurrent use results in a subjective
strengthening of the effect of the drug (Jones et al., 2012). Lindsey and colleagues
(2012) stated that individuals utilize these two drugs together to “amplify the high.”
As a result, these drugs have a high rate of co-administration and high potential for
abuse.
This high rate of co-administration has received much attention in the
literature as well as within the FDA (Phillips et al., 2017). Jones and McAnich
(2015) indicated that the co-administration of benzodiazepines and opioids have
been shown to contribute to up to one-third of the fatal opioid overdoses within the
United States, illuminating the significant risk associated with concurrent use. The
18

FDA has indicated that nonmedical use of both of these drugs has increased
significantly from 2004 to 2011 and that during this time, overdoses occurring from
co-administration have tripled. With such as high risk associated with concurrent
use, the FDA has moved forward with the addition of increased warnings on
packaging as well as the implementation of the use of a patient-focused medication
guide to disseminate information to patients about the significant risks associated
with concurrent use (FDA, 2016).
Cannabis. When Tetrahydrocannabinol (THC), the active ingredient in
Marijuana, enters into the body, it binds to cannabinoid receptors. This in turn
activates neurons in the brain, much like neurotransmitters (Lindsey et al., 2012).
The drugs ability to bind at these sites results in its ability to bring about its wellknown anxiolytic and sedative effects. The enzyme, which metabolizes THC, is
also responsible for the mediated metabolism of tricyclic antidepressants and
SSRI’s (Lindsey et al., 2012). As such, there is a significant possibility of
interaction effects between these two drugs.
Research conducted by Lindsey and colleagues (2012) has indicated that
cannabis, when used with tricyclic antidepressants, could result in symptoms of
mania and delirium. It was noted that when combined with barbiturates or
depressants, cannabis may lead to symptoms of sedation. Additionally, it was
reported that when utilized with lithium, cannabis use may influence increased
concentrations of lithium, potentially resulting in a concentration within the body
19

that extends beyond the therapeutic range and can result in adverse reactions
(Lindsey et al., 2012).
Notably, THC is categorized as a depressant and therefore, its use with other
CNS depressants may result in an intensifying effect. Severe CNS depression can
lead to an individual becoming unresponsive, unconscious and may even lead to
coma or ultimately death. The concomitant uses of these substances can lead to
fatal consequences.
Methamphetamine. Methamphetamine works like cocaine to increase levels
of neurotransmitters such as dopamine in the synapse (Lindsey et al., 2012). As
such, the result is an increase in positive emotions and alertness (Cruickshank &
Dyer, 2009). Although individuals use methamphetamines for the aforementioned
positive effects, there are negative effects associated with its use as well.
Methamphetamine also induces the release of catecholamine’s from the adrenal
glands. This can lead to the individual experiencing CNS stimulation, cardiac
arrhythmias and hypertension (Barr et al., 2006). Lindsey and colleagues (2012)
also noted important side effects of use to be anxiety, insomnia, paranoia and
hallucinations. This is important to note for clinicians, as psychotropic medications
prescribed for individuals may be to treat such symptoms, which are then
exacerbated by methamphetamine use.
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Impact of Substance Use Disorder on Medication Adherence
Substance use has been shown to negatively affect medication adherence
among mental health patients (Chandra et al., 2014, Manwani et al., 2007; Weiss,
2004). Previous research has indicated psychiatric patients with substance use
disorders (SUD) show high rates of treatment non-adherence (Herbeck, Fitek,
Svikis, Montoya, Marcus & West, 2005). In fact, a study conducted by Herbeck et
al. (2005) examined treatment adherence in individuals with comorbid SUD. A
component of their study involved surveying psychiatrists to determine rates of
adherence across their patients with this comorbidity. Results of this survey
indicated that the psychiatrists reported 40.5 percent of their clients with SUD
exhibited treatment adherence difficulties. The authors specified that this
percentage is representative of two out of five patients with a comorbid SUD
presenting with some form of medication non-adherence.
Schizophrenia. Olfson, Mechanic, Hansell, Boyer, Walkuo and Weiden
(2000) examined predictors of non-adherence with medications in a group of
patients with schizophrenia, following discharge from hospitalization. The authors
found three predictors of nonadherence in these participants: (a) history of nonadherence, (b) substance use, and, (c) refusal of family members to participate in
their treatment. Of these predictors, substance use was the strongest predictor of
patient medication non-adherence. Cannabis, in particular, was found to
significantly hinder adherence to medication in patients with schizophrenia (Miller
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et al., 2009).
Lacro and colleagues (2002) reported patients most often indicated factors for
non-adherence with medication to be poor insight into their illness, poor
therapeutic alliance, negative attitudes toward medication and substance abuse.
Chandra, Kalasapati, Mallepalli and Chada Muni (2014) also examined factors
effecting non-adherence in patients with schizophrenia. Like Lacro et al. (2002),
their study found substance abuse significantly contributed to non-adherence with
psychiatric medication.
Further examination of factors predicting adherence to medication among
patients diagnosed with Schizophrenia, was conducted by Novick, Haro, Suarez,
Perez, Dittmann and Haddad (2010). Specifically, this study examined the
predictors of patient’s adherence and non-adherence to prescribed antipsychotic
medications (Novick et al., 2010). The study looked to evaluate characteristics of
the patients, which were present at baseline, which could be predictive of greater
adherence to medication. Factors found to influence adherence to medication
adherence were patient’s previous hospitalizations, living independently and
hostility. In addition, as was seen in previous studies, the authors found that of the
patients who were found to be non-adherent, alcohol dependence and substance use
were shown to be significant risk factors for non-adherence (Novick et al., 2010).
Notably, the authors indicated that addressing substance use could be a potential
strategy for improving medication adherence within this population.
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Jonsdottir et al., (2013) also examined risk factors for medication nonadherence. Participants had either a diagnosis of bipolar disorder or schizophrenia.
The authors, like previous researchers, hypothesized the use of illicit substances or
alcohol would result in a decrease in adherence to prescribed medications. The
study found a relationship between substance use and non-adherence across both
diagnostic groups, although differences in the amount of substances and prevalence
of abuse were also seen. They noted that patients, who were partially adherent, used
illicit drugs more often than those who were identified as fully adherent.
Bipolar Disorder. Baldessarini, Perry and Pike (2008) examined risk factors
for non-adherence among patients diagnosed with Bipolar Disorder. Results of their
study indicated that, like Olfson and Colleagues (2000), the factor most strongly
associated with non-adherence within this population was substance use,
specifically alcohol-dependence. Perlis and colleagues (2010) reported alcohol use
disorder was significantly associated with pharmacologic non-adherence. Manwani
(2007) examined the effect of substance use on patient adherence to prescribed
mood stabilizers. Results of their study noted significantly lower levels of
adherence in individuals who indicated the use of illicit substances.
Teter, Falone, Bakaian, Tu, Ongur and Weiss (2011) examined the impact
of current, past (no use for at least one year) and no substance use disorder on
medication adherence in individuals with Bipolar Disorder. The authors
hypothesized that individuals with current substance use disorder (SUD) would
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exhibit lower rates of adherence to medication and show increased negative
attitudes toward the use of medication treatments. Additionally, it was
hypothesized that similar attitudes toward medication and rates of adherence would
be seen across the no SUD and past SUD groups. Results of the study indicated that
participants who were using substances during treatment exhibited higher rates of
non-adherence and more negative attitudes regarding medication use than the no
substance use or past use patients. Individuals with past history of use and those
with no history were shown to exhibit similar medication adherence behaviors
(Teter et al., 2011).
A literature review conducted by Pompili, Venturini, Palermo, Stefani,
Seretti and Lamis (2013) examined studies related to predicting non-adherence to
medication in individuals with mood disorders (i.e., bipolar disorder, major
depressive disorder, and dysthymic disorder. The author’s analysis included 54
articles published between 1988 and 2012. Predictors of non-adherence within the
studies included in the analysis were sociodemographic factors, physical and
psychiatric comorbidity, patient beliefs, the relationship between patient and
doctor, clinical characteristics of the disease, and characteristics of treatment.
Following analysis, the authors noted that comorbid SUD was found to be
the most important predictor of non-adherence in individuals with BD, although it
was also noted that comorbid SUD may also decrease adherence in individuals
diagnosed with depression.
24

Depressive Disorders. A study conducted by Akerbald, Bengtsson,
Holgersson, Knorring and Ekselius (2008) examined risk factors for non-adherence
with antidepressant medication in patients with a diagnosis of Major Depressive
Disorder. The authors noted that there were certain patient, as well as illness-related
factors, which resulted in the individual being more likely to not comply with
medication instructions. Of these factors, they identified substance abuse to be one
of the significant predictors of non-adherence to medication (Akerbald et al., 2008).
Zivin, Ganoczy, Pfeiffer, Miller and Valenstein (2009) examined
antidepressant adherence in Veteran patients diagnosed with depressive disorder
and discharged from a psychiatric hospital. To evaluate medication adherence, the
authors calculated medication possession ratios (MPR) from information received
from the VA pharmacy, approximately three to six months following discharge
(Zivin et al., 2009). These numbers were then compared to patient demographic
and clinical factors such as diagnoses to determine if any relationship existed. The
authors indicated a score of 0.8 to reflect good adherence, as this indicated that
patients took 80% of the medication they were prescribed.
Results indicated 49% of patients showed adherence rates below 80%, with
27% of patients taking medication less than 50% of the time. Notably, the results
of the comparison of adherence and clinical predictors indicated that patients, who
had comorbid SUD, were more likely to exhibit poor adherence to medication
(Zivin et al., 2009). This relationship was expressed by an adjusted odds ratio of
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1.86; indicating that non-adherence is 86% more likely in individuals with a
comorbid SUD. It was additionally noted that due to the large sample size used
within this study, a odds ratio of greater than 1.3 is less likely to be due to a false
positive and therefore, more likely to indicate a true predictor of non-adherence.
Substance Use Frequency and Medication Adherence
Without a doubt, substance use has a negative effect on medication adherence
in psychiatric patients. Previous research has consistently identified substance use a
significant predictor of non-adherence with psychotropic medication among a
variety of mental health diagnoses. It has also reiterated the importance of
obtaining a thorough understanding of this relationship to provide treatment that is
more effective to mental health patients. Therefore, although the relationship
between substance use and medication adherence has been well established, the
relevant features of this relationship such as intensity or frequency of use, have
received less attention.
Magura, Rosenblum, and Fong (2011), examined predictors of
medication non-adherence in psychiatric patients with substance use histories. In
addition to examining medication-related risk factors, psychological risk factors,
and social/environmental risk factors, the researchers examined the effect of the
intensity of substance use on rates of non-adherence. During their intake, patients
were asked within the past 90 days, how many days had they used illicit drugs (i.e.,
alcohol, marijuana, cocaine, heroin or other opioids, methadone, hallucinogens,
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barbiturates, sedatives, stimulants, ecstasy and inhalants). The authors indicated
that a higher score was indicative of more alcohol or drug use. Their study found
no association between the intensity of substance use and non-adherence with
medication (Magura et al., 2011). The authors indicated that these results were
similar to that of Lacro and colleagues (2002), which also found no significant
difference across intensity of use. That is, utilization of drugs or alcohol may serve
more as a qualifier that influences one’s ability to be compliant with psychotropic
medications, instead of a predictive qualifier of the severity of the non-adherence.
They stated that:
It might be surprising that the intensity of substance use was not associated
with medication adherence, but this is not necessarily inconsistent with prior
research, which generally has found differences in adherence between those
with and without substance use, rather than between those varying degrees of
use (Magura et al., 2011).
The authors cite Lacro and colleagues (2002), a literature review, which
found that 5 out of 9 studies, examining the effect of a substance use on medication
adherence, indicated a significant association. Notably of these 5 studies, only one
study conducted by Drake, Osher, and Wallach (1989) examined varying intensity
of use. Drake and colleagues (1989) examined the association between mild to
severe alcohol use and medication adherence, street drug use, psychiatric
symptoms, medical problems and hospital tenure (i.e., re-hospitalization and days
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spent in the hospital). The authors indicated alcohol use was significantly
associated with medication non-adherence. They also noted that rates of nonadherence with medication increased with increased alcohol use. Specifically, the
authors found that individuals who did not use alcohol showed a 22% medication
non-adherence rate, similar to individuals who were identified to drink a mild
amount of alcohol who showed a 19% non-adherence rate (Drake et al., 1989).
Moderate drinkers were shown to have a 38% non-adherence rate, severe drinkers a
44% non-adherence rate and extremely severe drinkers showed a 50% nonadherence rate (Drake et al., 1989).
Magura, Mateu, Rosenblum, Matusow and Fong (2014) furthered the study
of medication adherence by examining non-adherence in psychiatric patients who
have a history of substance use, using a larger sample size obtained across multiple
locations. Like the previous studies, Magura and colleagues (2014) examined
sociodemographic variables, medication adherence, medication risk factors and
psychological risk factors. Looking to add to the previous literature, the authors
also examined social/environment risk factors for non-adherence. This variable
consisted of an evaluation of the participant’s level of support (both medical and
social), finances, living arrangements, and behavior risk factors (Magura et al.,
2014). Behavior risk factors were comprised of alcohol or illicit drug use, excessive
alcohol use, urge to use, criminal justice involvement and alcohol or drug recoverygroup attendance (Magura et al., 2014).
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The authors examine these relationships using a linear regression. Their
study found that of the behavioral risk factors, alcohol use or drug use, urge to use,
criminal justice involvement and excessive alcohol use were found to significantly
predict non-adherence (Magura et al, 2014). The authors then utilized a backward
elimination procedure. The results of this statistical analysis showed excessive
alcohol use continued to be a significant predictor of medication non-adherence,
while alcohol and drug use was found to no longer show significance (Magura et
al., 2014).
With this is mind; it is plausible to say that more excessive use of alcohol
predicted non-adherence above and beyond that of alcohol or drug use alone. As
such, it is possible, although it was not directly tested in this study, that intensity of
use would be a significant predictor of non-adherence, like was seen in Drake and
colleagues (1989).
Rationale for Proposed Study
With the ever-increasing rates of prescription drug utilization in the United
States, and the significant increase in rate of prescribing, prescription drug use is
becoming an increasingly important field of study. Previous studies have
elucidated the significant rates of non-adherence to medication, particularly in the
mental health field. Additionally, it was noted that medication adherence is a
critical factor in the effectiveness of treatment and overall clinical outcomes for
patients.
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Several factors effecting non-adherence have been studied, and of these
factors, substance use has been identified to be a significant predictor. When
studying non-adherence in individuals with mental health diagnoses, in particular,
this information is especially important as many disorders show a high rate of
comorbid SUD or related sub-clinical substance use. As such, these individuals
have the potential to be at a higher risk for non-adherence with medication and, in
turn, its adverse effects on treatment and outcomes.
So, do different rates of use result in a higher likelihood of non-adherence?
Whereas previous studies have shown substance use to have a significant impact on
patient adherence to prescribed medication, the research examining the effects of
the dimensions of its use have had mixed results (Drake and colleagues, 1989;
Lacro and colleagues, 2002; Magura et al., 2014). Therefore, with little definitive
research conducted examining the effect of the intensity of substance use on nonadherence with medication, the present study will look to further examine this
relationship. Obtaining this information will provide both clinicians and providers
within the field a greater understanding of the effect of substance use on the
effectiveness of treatment with psychotropic medications.
Study Objectives and Hypotheses
The examination of existing literature has indicated that psychotropic
medication adherence is significantly influenced by substance use in individuals
with mental health diagnoses. Obtaining a greater understanding of this relationship
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is paramount, as medication non-adherence has adverse effects on treatment
effectiveness and overall patient outcomes. Gaining a comprehensive
understanding requires examining more thoroughly the dimensional aspects of the
factors known to influence adherence; in this case the effect of intensity of use.
Therefore, this study will attempt to: (1) add to the existing literature examining the
effect of substance use on non-adherence with psychotropic medication use, and (2)
examine the effect of varying intensities of drug use on rates of non-adherence with
prescribed psychotropic medication. Once completed, this information will provide
mental health professionals with invaluable information needed for program
development and ensuring more effective treatment outcomes.
Based on the reviewed literature relating to this project, the following are
hypotheses of the proposed study:
1. Indication of a substance use will significantly predict medication nonadherence in patients prescribed psychotropic medications.
a. Approximately 25% (or greater) of patients in this study will have
used some type of illicit drug or alcohol while taking prescription
medication.
b. Approximately 50% (or greater) of patients will demonstrate nonadherence to medications prescribed.
2. Significant differences in the effect on medication adherence will be seen
across varying degrees of substance use.
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3. Substance use intensity will have a positive correlation with medication
non-adherence.
Method
Procedure
This study was approved by the Florida Institute of Technology Institutional
Review Board (IRB) prior to participant recruitment. Participants were recruited
from within two local, Circles of Care Inc., community mental health clinics.
Circles of Care, Inc. is a non-profit mental health-based program comprised of
inpatient, crisis services, and outpatient mental health care services through its
hospital-based and State and County contracted programs. Circles of Care has 52
licensed hospital beds, 50 state licensed adult crisis stabilization beds, 78 licensed
residential and treatment beds, 18 licensed chemical dependency detoxification
beds, 12 licensed chemical dependency intensive residential treatment beds, 16
children's crisis stabilization beds as well as a complete continuum of outpatient
care to provide services to residents of the Brevard County community. Permission
was granted to the authors to survey and collect data from the clients at their two
local outpatient clinics. Data was collected via a self-report survey. Participants
were provided with a paper copy of the informed consent and survey as part of their
intake packet for treatment (see Appendix A and B).
Patient’s responses were kept confidential and they were not asked to
identify themselves on the questionnaire. The informed consents were kept in a
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separate file from the surveys that were collected. This allowed there to be no
matching of informed consent with survey data and maintain the confidentiality of
the participant. Inclusion criteria for the study consisted of participants (1) being
over the age of 18, (2) prescription of a psychotropic medication, and (3)
concurrent illicit drug use.
Outcome Measures
The survey was created specifically for use within this study. The survey
requested demographic information, information pertaining to prescribed
psychotropic medications and subjective measures of adherence and non-adherence
with prescription instructions. Adherence with medication was evaluated using a
Likert scale. The Likert scales provided a measure of the participant’s compliance
with their prescribed dosage guidelines and their likelihood of terminating
medication use without consulting their prescribing doctor. An example of one of
the Likert Scale questions on the survey is as follows:
Of the medications circled above, and is prescribed daily, (Please write in
your medication) ________________, How often do you take half, or less
than half of the recommended dosage of this medication?
The participants were then provided a Likert Scale from 1 (Never) to 4 (Always). If
medication non-adherence was identified, patients were then asked to identify the
factor(s) that function as a barrier to their medication adherence. Additionally, the
questionnaire utilized questions from the Drug Use Screening Inventory-Revised
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adult survey (DUSI-R). The DUSI-R is a self-report questionnaire used to examine
the severity of problems in 10 domains, one of them being substance use. For the
purpose of this study, only the component of the DUSI-R, which is used to screen
for involvement with drugs, was utilized. This measure allowed the researchers to
analyze potential associations between rate of medication non-adherence and
frequency of drug use. The participants were asked to identify each substance used
within the past year, and how many times it was used per month.
Data Analysis
The questionnaire utilized four types of questions to measure rates of
participant adherence and non-adherence to medication. Two types of questions
asked participants to rate nonadherence on a Likert scale, while the other two asked
for the same ratings pertaining to adherence. To obtain an overall nonadherence
score, responses to questions pertaining to adherence were reverse coded to reflect
a rate of non-adherence. Then, ratings across all questions were summed to obtain
an overall nonadherence score for each participant. Similarly, substance use scores
consisted of the sum of the Likert responses across each substance, for each
participant.
To test our first hypothesis the continuous variable of substance use score was
transformed into a categorical variable with two conditions: people who indicated
using substances and people who did not. With this categorical variable and the
continuous variable of non-adherence score, an independent samples T-test was run
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to determine if there was a significant difference in non-adherence between
substance users and non-users.
To identify the percentage of individuals within our sample which indicated
using substances, descriptive statistics pertaining to the substance users and nonuser’s variable were explored. In order to identify the percentage of individuals
who were non-adherent to medications, non-adherence scores were standardized to
identify the mean of non-adherence scores. The selected criteria for non-adherence
for our study, was defined as an individual’s non-adherence to medication greater
then 50% of the time. With the identified mean score, the researchers were able to
ascertain the number of individuals falling above this score and obtain a percentage
of individuals who are identified as non-adherent.
For our second hypothesis the variable of substance use score was
standardized to identify the mean. Substance use was then transformed into a
categorical variable of above and below average substance users. An independentsamples t-test was then conducted to compare medication non-adherence, using
non-adherence scores, and the dichotomous variable of below average users and
above average users. This would allow the researchers to examine the effect of
intensity of use on medication nonadherence.
Lastly a simple linear regression was used to examine the relationship
between intensity of use and adherence. The continuous variables of substance use
scores and non-adherence scores were used. The strength and direction of the
35

correlation was then examined to determine the relation between these two factors.
The aforementioned analyses were completed using the Statistical Package for
Social Sciences (SPSS).
Results
Participants
In total, 237 participants completed the survey. A total of 42 cases were
deleted, due to missing values in regard to compliance data. As compliance
behavior was the primary variable of interest, participants who did not disclose this
information, were therefore removed from the study. After cleaning the data, 195
participants remained and were included in data analysis. Descriptive statistics for
participants can be seen in Table 1 of the appendix.
Of the participants that were included in our study, 31.8% (n = 62) were
male and 68.2% (n = 133) were female. 36% (n =69) were between the ages of 4155, 29% (n = 55) were between the ages of 26-40, 18% (n =34) were between the
ages of 56-65, 8% (n =15) were between the ages of 66-74, 5% (n = 9) were
between the ages of 18-25, and 3% (n = 6) were 75 and above.
The participants were 83% (n = 161) Caucasian, 8% (n = 16) African
American/Caribbean, 4% (n = 8) Hispanic, 1% (n = 3) Asian, 2% (n = 4) American
Indian or Native American, and 1% (n = 3) selected other. Approximately 82% (n =
153) of participants indicated a heterosexual orientation. 8% (n = 15) indicated that
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they were bisexual, 8% (n = 15) preferred not to report, and 2% (n = 4) reported a
homosexual orientation.
The most frequently endorsed level of education was a high school diploma
or GED (n =83: 43%), followed by an associate’s degree (n = 39 : 20%), no high
school diploma or GED (n = 23 : 12%), a bachelor’s degree (n = 21 : 11% ),
attended a trade school (n = 17 : 9%), and 5% (n = 9) of participants had a postsecondary degree. 72% (n = 138) indicated that they were currently unemployed.
15% (n= 29) reported they were employed full-time. 13% (n = 24) reported being
employed Part-time.
Of the participants who chose to respond, 62% (n = 120) indicated that they
had been previously hospitalized while 38% (n = 72) reported no history of
hospitalization.
Statistical Analyses
Percentages of illicit substance use and noncompliance. The first
hypothesis proposed that over 25 percent of participants would engage in substance
use and over 50 percent of participants would demonstrate non-adherence to
prescribed medication. The survey was answered by 195 participants, of whom 80
percent were found to engage in substance use. This was determined by utilizing
the dichotomous variable of substance use users and nonusers created previously.
Frequency statistics indicated 60 percent of participants engaged in the use of illicit
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substances. This statistic excluded tobacco and alcohol as these are considered legal
substances. When alcohol used was added, the percentage of use increased to 73
percent.
Analysis of frequency statistics also indicated that 50.3% percent of all
participants were shown to display above average medication noncompliance.
Therefore, the hypothesis indicating 50 percent of participants would demonstrate
non-adherence to prescribed medication, was supported.
Substance use and medication non-adherence. The other portion of our
first hypothesis proposed that substance use would significantly predict nonadherence to prescribed medications. An independent-samples t-test was
conducted to compare medication non-adherence between substance users and
nonusers. Levene’s test showed the variances for non-adherence for both groups to
be equal, therefore, equal variances are assumed, F (195) = 2.10, p >.05. There was
no significant difference in medication non-adherence for substance non-users (M =
11.76, SD = 8.33) and substance users (M = 12.65, SD = 7.47); t (195) = -.64, p =
.57, two-tailed. The magnitude of the differences in the means (M difference = -.89,
95% CI [-3.62, 1.82]) was small (Cohen’s d = 0.11). The hypothesis that substance
users would show a greater amount of medication non-adherence was not
supported.
Noncompliance and intensity of substance use. The second hypothesis
proposed that significant differences in the effect on medication adherence will be
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seen across varying degrees of substance use. An independent-samples t-test was
conducted to compare medication non-adherence between below average users and
above average users to examine the effect of intensity of use. Levene’s test showed
the variances for non-adherence for both groups to be equal, therefore, equal
variances are assumed, F (163) = 2.0, p >.05. There was no significant difference in
medication non-adherence for below average substance users (M = 13.52, SD =
7.88) and above average substance users (M = 12.03, SD = 7.06); t (163) = 1.18, p
= .24, two-tailed. The magnitude of the differences in the means (M difference =
1.48, 95% CI [-.99, 3.96]) was small (Cohen’s d = 0.19). The hypothesis that
intensity of substance use would show a greater amount of medication nonadherence was not supported.
The third hypothesis proposed that substance use intensity will have a
positive correlation with medication non-adherence. A simple linear regression was
used to examine the relationship between non-adherence and intensity of substance
use. Results indicated an inverse relationship between the intensity of use and
medication non-adherence, r (163) = - .11, p > .05. This relationship was not shown
to be statistically significant.
Discussion
Impact of Study
Psychotherapy excluded, psychotropic medication is the primary treatment
modality for individuals undergoing mental health treatment. Although frequently
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prescribed by providers, the psychotropic medication regimen is rarely adhered to
by patients in a way that maximizes treatment efficacy. Non-adherence to
medication has been shown to have disastrous effects on patient outcomes and has
elicited the interest of many previous researchers (Chapman & Horne, 2013; De
Las Cuevas et al., 2017; Magura et al., 2014). Notably, individuals undergoing
mental health treatment have also been shown to exhibit high rates of comorbid
substance use, which has been identified by previous research to be a significant
predictor for non-adherence. With the high rates of substance use among
individuals receiving psychotropic medication, it is imperative to gain a greater
understanding of the relationship between substance use and medication nonadherence, warranting a more in-depth analysis undertaken by the current research.
Adding to the existing literature, this study examined the frequency of
concurrent substance and psychotropic medication use amongst patient attending
treatment within an outpatient clinic. We hypothesized that approximately 25
percent of patients in this study would have used illicit drugs or alcohol while
taking prescription medication. Results indicated 73 percent of individuals engaged
in illicit substance and alcohol use concurrently with medication, thus, supporting
our hypothesis.
The data collected through this study goes above and beyond that which
was hypothesized. That is, 80 percent of individuals surveyed indicated engaging in
some form of substance use (i.e., illicit drugs, alcohol and tobacco). And as was
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previously noted, 73 percent reported engaging in illicit drugs and/or alcohol use.
The results are consistent with the high rates of comorbidity between mental illness
and substance use identified in the previous literature (Herbeck, Fitek, Svikis,
Montoya, Marcus & West, 2005; Substance Abuse and Mental Health Services
Administration, 2017). Specifically, research conducted by the SAMHSA in 2017,
which identified 8.2 million individuals within the United States were diagnosed
with co-occurring mental and substance use disorders. As the study was conducted
within a mental health treatment facility, it is plausible that these high rates of
comorbid SUD are being reflected in our obtained rates of participant substance
use.
This study also hypothesized that approximately 50% of patients would
demonstrate non-adherence to the psychotropic medications that they were
prescribed. This hypothesis was substantiated by our results. Results indicated that
50.3% of participants reported non-adherence to their psychotropic medications.
This finding is consistent with the previous literature which indicated an average of
52 percent of participants reporting non-adherence to medication (Sansone
&Sansone, 2012).
One factor specific to the community surveyed was demographics of this
underserved mental health setting. As such, patient factors such as their
socioeconomic status coupled with the cost and availability of these medications
may be a factor affecting participant adherence. Additionally, as was noted within
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the previous research, substance use has been shown to significantly influence
patient medication adherence. As participants were receiving treatment for mental
health difficulties, and there is a high rate of comorbidity with substance use, it is
plausible to see high rates of non-adherence to medications within this setting and
population specifically. This, therefore, is one explanation for the commiserate
result founded regarding non-adherence to medication.
Contrary to our hypothesis, a significant relationship between substance use
and medication non-adherence was not found. This finding is inconsistent with the
previous literature conducted by Drake and colleagues (1989), Lacro and
colleagues (2002), and more specifically Magura et al. (2014); one of the studies
for which the current study wished to expand. As previously discussed, the
relationship between substance use and medication non-adherence had been
relatively well established within the literature, although a similar result was not
seen within the current research study. It is possible that the variability in both
population, as well as SUD, may have impacted the observed relationship as it
related to medication non-adherence. Also, sample size (as will be discussed later)
may have been a factor in getting a generalizable enough demographic to be
comparable to the literature suggestions.
A literature review conducted by Hendershot and collogues (2010),
evaluated previous studies examining of the effects of alcohol use on antiretroviral
medication adherence. Through their research they noted several variables which
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were identified to moderate this relationship. They noted a stronger association
between alcohol use and non-adherence to medication among samples which
contained a higher of number of males then females, studies which utilized a larger
sample size, ones which measured alcohol use quantity as opposed to frequency,
studies which utilized greater stringency when defining adherence, and those which
utilized assessments that were not self-report measures. In fact, the authors
indicated that especially for adherence measurement, the use of more objective
measures such as a Medication Event Monitoring System (MEMS), produced the
most reliable results. This system uses a cap that is placed on a medicine bottle, and
records data on the date and time it is opened and closed. This method decreases
areas of potential measurement error.
The moderating factors noted by Hendershot and collogues (2010),
specifically, the use of a questionnaire and the measures of substance use, may
have significantly impacted the ability of the current study to obtain significant
results. The questionnaire was not an objective measure and therefore was likely
affected by participant error. Additionally, the current study measured substance
use by inquiring about participants frequency of use, as opposed to quantity of use.
As we did not examine the moderating effects of these factors specifically, we are
not able to speak to their potential effect on participant non-adherence within this
study. We do, however, urge future researchers to continue to examine the potential
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impact of these factors on the association between medication non-adherence and
substance use.
Additionally, this study found no significant relationship between intensity
of use and non-adherence to psychotropic medications. Research conducted by
Jonsdottir et al., (2013) indicated differences in adherence rates across participants
engaging in differing quantities of drug use. Similar results were seen in the
research conducted by Magura et al., (2014) which found excessive alcohol was a
stronger predictor of non-adherence in patients, above and beyond that of alcohol
and drug use alone. Although the results of the current study did not support the
results of the studies conducted by Jonsdottir et al., (2013) and Magura et al.,
(2014), they are commensurate with the results of the studies conducted by Lacro et
al., (2002) and Magura and collogues ( 2011). The data collected by Magura et all,
(2011) indicated no association between the intensity of substance use and greater
non-adherence to medication. The authors noted a tendency to find differences
between groups of users and non-users, as opposed to within groups of users of
varying intensities. As previous studies have shown varying findings concerning
the association between these two factors, this area, in particular, should continue
to receive attention in future research.
Lastly, we hypothesized that substance use intensity would have a positive
correlation with medication non-adherence. Consistent with previous literature, our
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study found no significant association between the intensity of substance use and
non-adherence with medication.
As indicated in our review of the literature, the high rates of comorbidity
between psychiatric and substance use disorders lays the groundwork for
polypharmacy. With polypharmacy comes the potential for drug-drug interactions,
which although often detrimental to the health of patients, may also be a factor
influencing medication adherence. For example, patients may be utilizing some
medications in hopes of increasing the effects of illicit drugs, or vice versa.
Therefore, as substance use increases, there is the potential for an increase in use of
prescribed medication, as seen within the current study. Future research may wish
to examine the influence of interaction effects on medication adherence rates, in
individuals who engage in substance use concurrently with prescribed medication.
Limitations and Areas for Future Research
Small sample size. As previously discussed, the nonsignificant results
obtained within this study may be the result of a lack of power due to a small
sample size. A larger sample size may increase the chances of detecting a true
effect within the data. As such, future studies may consider increasing the sample
size to allow for more reliable results with greater power to detect differences.
Validity of the Questionnaire. The questionnaire used was adapted for this
study using questions created by the researchers, as well as those adapted from the
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Drug Use Screening Inventory-Revised adult survey (DUSI-R). As there was no
pilot study to establish the validity of the questionnaire for evaluating these factors,
there is the potential that the developed questionnaire did not accurately measure
the constructs we set out to measure. As the DUSI-R is a reliable and valid selfreport measure, and the questions from the DUSI-R coupled with the questions
created by the researchers appeared to effectively examine the constructs within
this study, we felt it was the best available option to utilize this original
questionnaire. Future research may wish to utilize a questionnaire, whose validity
has been confirmed and used within previous studies.
Additionally, as was mentioned by Hendershot and collogues (2010) and
Haddad, Brain, and Scott (2014), the use of subjective self-report measures to
identify non-adherence has been shown to have poor validity and a tendency to
underestimate rates of nonadherence within the sample. Therefore, more objective
measures such as a MEMS system, can be utilized within future research to combat
any errors which may occur when using more subjective measures.
Participant Bias. The survey asked participants to disclose information
about sensitive topics such as drug use and medication taking behaviors.
Participants may wish to present themselves, and their behaviors in a more positive
light, by underreporting such behaviors. This may increase error in the research
data and contribute to the difficulty detecting differences between groups.
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Although the experimenters took measures to deter such a bias, such as
informing the participants of confidentiality and anonymity within the informed
consent, participants may still have responded in ways that would minimize
disclosure about the variable of interest within this study. Future studies may
examine the use of other measures, which minimize the potential for social
desirability biased responding.
Conclusion
The study was conducted in an effort to add to the existing literature
examining medication nonadherence and substance use. The current study looked
to expand the research examining the relationship between substance use and noncompliant medication behavior, as well as evaluate the effect of intensity of
substance use on non-adherence. Furthermore, previous research has been variable
in its findings, and as such, warranted further examination.
Results obtained in this study continue to highlight the high frequency of
patients utilizing substances concurrently with prescribed medications. Previous
research has shown that substance use affects medication adherence, and although
not seen within the current study, this information remains important not only for
medical professionals but also clinicians as concurrent use raises concerns about
the treatment approaches utilized. Additionally, drug-to-drug interactions,
expectations of prescribed drug effect and duration, and self-medication all remain
areas of complicated concern among patients in this demographic. As intensity of
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use was not shown to have a significant effect on non-adherence, emphasis should
therefore not only be placed on those who exhibit more intense drug use, but on
any drug use disclosed by the patient. With this knowledge, doctors and clinicians
are better equipped in the battle against medication non-adherence. Understanding
the factors affecting medication non-adherence is advantageous in the development
of strategies to increase adherence in patients and improve overall patient
outcomes.
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Table 1
Descriptive Statistics of Participant Demographic Information
Variable
Race and Ethnicity
African American/Caribbean
American Indian or Native American
Asian
Caucasian
Other
Hispanic
Age
18-25
26-40
41-55
56-65
66-74
75+
Educational Attainment
No High School Diploma or GED
High school Graduate or GED
Trade School
Associates Degree
Bachelor’s Degree
Master’s Degree
Doctoral Degree
Sex
Male
Female
Sexual Orientation
Heterosexual
Homosexual
Bisexual
Prefer Not to Say
Employment Status
Full-Time
Part-Time
Unemployed
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N

Percent

16
4
3
161
3
8

8.2%
2%
1.5%
82.6%
1.5%
4.2%

9
55
69
34
15
6

5%
29%
34%
18%
8%
3%

23
84
18
39
21
10
0

12%
43%
9%
20%
11%
5%
0

62
133

31.8%
68.2%

156
4
16
16

81%
2%
8%
8%

29
24
138

12%
10%
58%

Appendix A
Demographics
What is your age: (Check One)
18-25

26-40

41- 55

56-65

66-74

75+

What is your gender: (Check One)
Male

Female

Prefer not to say

What is your ethnicity: (Check One)
Caucasian

African American/ Caribbean American

Pacific Islander

Hispanic

Native American/ American Indian

Asian

What is your highest level of education: (Check One)
Did not complete High School
Bachelor’s Degree

High School Diploma/ GED
Master’s Degree

Associates

Doctorate

Trade school Certification
What is your current employment status: (Check One)
Full-Time

Part-Time

Unemployed

What is your sexual orientation: (Check One)
Heterosexual

Homosexual

Bisexual

Prefer not to say

What is your marital status: (Check One)
Single/ Never Married

Legally Separated

Divorced

Widowed

Medical History:
Have you ever been hospitalized overnight due to a psychiatric condition: (Check
One)
Yes

No
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Are you currently prescribed any of the following medications? (Circle any/ and all
medications that you are currently prescribed)
Antidepressants

Anticonvulsants

Anafranil (Clomipramine)

Neurontin (Gabapentin)

Tofranil (Imipramine)

Klonopin (Clonazepam)

Lexapro (Escitalopram)

Tegretol (Carbamazepine)

Prozac (Fluoxetine

Keppra (Levetiracetam)

Paxil (Paroxetine)

Depakote (Valproic Acid)

Celexa (Citalopram)
Zoloft (Sertraline)

Beta Blocker

Effexor (Venlafaxine)

Ternormin (Atenolol)

Luvox (Fluvoxamine)

Metoprolol (Lopressor)

Desyrel (Trazadone)

Anti-anxiolytics/Sedative

Antipsychotics

BuSpar (Buspirone)

Clozaril (Clozapine)

Ativan (Lorazepam)

Thorazine (Chlorpromazine)

Valium (Diazepam)

Haldol (Haloperidol)

Xanax (Alprazolam)

Seroquel (Quetiapine)

Librium (Chlordiazepoxide)

Geodon (Ziprasidone)
Elavil (Amitriptyline)
Abilify (Aripiprazole)
Risperdal (Risperdone)
Zyprexa (Olanzapine)
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Other _________________________ (Please write in medication)
If you have more than one prescribed medication, please answer for each separate
medication in section 1, 2, and 3
Section 1:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines on the
label?
Please circle your answer below:
1
Never

2
Rarely

3
Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines on the
label?
Please circle your answer below:
1
Never

2
Rarely

3
Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
_________________, How often do you full comply with the dosage guidelines on the
label?
Please circle your answer below:
1
Never

2
Rarely

3
Most of the time

4
Always

Section 2:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the recommended
dosage of this medication?
1
Never

2
Rarely

3
Most of the time
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4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the recommended
dosage of this medication?
1
Never

2
Rarely

3
Most of the time

4
Always

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take half, or less than half of the recommended
dosage of this medication?
1
Never

2
Rarely

3
Most of the time

4
Always

Section 3:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication completely,
without first consulting your prescribing doctor?
1
Never

2
Unlikely

3
Likely

4
Highly Likely

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication completely,
without first consulting your prescribing doctor?
1
Never

2
Unlikely

3
Likely
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4
Highly Likely

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How likely are you to stop taking this medication completely,
without first consulting your prescribing doctor?
1
Never

2
Unlikely

3
Likely

4
Highly Likely

Section 4:
Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
1
Once

2
Twice

3
Three or more

4
As needed

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
1
Once

2
Twice

3
Three or more

4
As needed

Of the medications circled above, and is prescribed daily, (Please write in your
medication)
________________, How often do you take this medication on a daily basis?
1
Once

2
Twice

3
Three or more

4
As needed

Section 5:
Please circle your answer below:
The majority of the time I take the above medication by myself, without assistance or
prompting.
The majority of the time a friend or family member encourages, assists, or reminds me to
take the above medication in some way.
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Section 6:
If you answered less than 4 for any of the above questions, what are sometimes
barriers (factors that get in the way) for taking your medication on-time and/or
consistently? (Circle all that apply)
Financial issues/Limitations

Forgetting

Religious Reasons

Side Effects (e.g. impact on appetite, nausea, drowsiness)
History of Addiction

Find it to be an inconvenience

Instructions too complicated

Unsure if medications are working

Other___________________
Section 7:
Of the above circled, Please rank the top three barriers of medication compliance
beginning with the most significant barrier as #1.
(Please write in answer):
#1 __________________________
#2 __________________________
#3 __________________________
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Section 8:
Ordinarily, how many times each month have you used each of the following drugs in
the past year? (NOTE: If you have only used a drug a few times over this past year,
answer “0 times”)
Circle your response:
Alcohol

0 times

1-2 times

3-9 times

10-20 times

Amphetamines/
Stimulants/ “uppers”
Cocaine/Crack

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

Prescription diet pills

0 times

1-2 times

3-9 times

10-20 times

Heroin/morphine
/opiates
Methadone

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

Prescription pain
killer pills
Barbiturates

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

Quaaludes

0 times

1-2 times

3-9 times

10-20 times

Tranquilizer Pills

0 times

1-2 times

3-9 times

10-20 times

LSD/Hallucinogens

0 times

1-2 times

3-9 times

10-20 times

Ecstasy

0 times

1-2 times

3-9 times

10-20 times

PCP

0 times

1-2 times

3-9 times

10-20 times

Marijuana

0 times

1-2 times

3-9 times

10-20 times

Glue

0 times

1-2 times

3-9 times

10-20 times

Gasoline or
other fumes
Smoking
Tobacco
Chewing
Tobacco
Anabolic Steroids

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

0 times

1-2 times

3-9 times

10-20 times

Which drug causes
you the most
problems
Which drug do
you prefer the most

68

More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times
More than 20
times

Appendix B
Informed Consent
Please read this consent document carefully before you decide to participate
in this study. The researcher will answer any questions before you sign this form.
Study Titles:
Medication Non-Compliance: Compliance to Psychotropic Medications within Community
Mental Health.
The Impact of Illicit Drug Use on Prescribed Psychotropic Medication Adherence.
Purpose of the Study: The purpose of the current study is to identify factors that prevent
individuals from fully taking their medications as prescribed. One of the factors that will be
investigated further, is the effect of different levels of drug use on the medication taking
behavior of individuals who are prescribed psychotropic medications. Participants are
chosen on a voluntary basis, and this study is offered to anyone attending outpatient
therapy.
Procedures: Participants will be asked to sign this form, as well as complete the short,
attached, survey. The survey will ask for some general demographic information as well
information about current medications, how often the individual takes half or less than half
of the recommended dosage of the medication, and some potential reasons that may
prevent the individual from fully taking the medication as prescribed. Additionally,
individuals will be asked about their drug use. If drug use if identified, individuals are
asked how many times each month have they used, within the past year.
Potential Risks of Participating: Risks to participants are no more than what is
experienced in everyday life.
Potential Benefits of Participating: Participation would allow the medication providers,
as well as mental health professionals, to identify factors that prevent individuals from
taking their medication fully as prescribed. This will help to develop programs to make
medication adherence easier for the participants, resulting effective treatment and
improved outcomes for patients.
Confidentiality: All information will be kept completely confidential. After it is collected,
the informed consent form will be kept separate from the survey form so there will be no
way to match a name to the survey and ensure the information provided cannot be
connected to the individual. Instead of using any identifying information on the survey,
responses will be assigned a code number. The list connecting your name to this number
will be kept in a locked file in the Florida Institute of Technology Psychology Department.
Your name will not be used in any report. The only individuals who will have access to
your responses are the principal investigators and their advisor. When the study is
completed and the data has been analyzed, the data will be destroyed.
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Voluntary participation: Your participation in this study is completely voluntary. There
is no penalty for not participating. If you wish to not participate, this will not impact your
ability to receive your prescribed medications. You may also refuse to answer any of the
questions we ask you.
Right to withdraw from the study: You have the right to withdraw from the study at any
time without consequence.
Whom to contact if you have questions about the study:
Emily E. DePetro MS, Principle Investigator
150 West University Blvd.
Melbourne, FL 32901
Email: edepetro2016@my.fit.edu
Lauren N. Stroker MS, BCBA, Principle Investigator
150 West University Blvd.
Melbourne, FL 32901
Email: Lstroker2014@my.fit.edu
Whom to contact about your rights as a research participant in the study:
Dr. Lisa Steelman, IRB Chairperson
150 West University Blvd.
Melbourne, FL 32901
Email: lsteelma@fit.edu Phone: 321.674.8104

Agreement:
I have read the procedure described above. I voluntarily agree to participate
in the procedure and I have received a copy of this description.
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